The Household Economic Burden of Non-communicable Diseases in 18 Countries

Background: Non-communicable diseases (NCDs) are the leading cause of death globally. In 2014, the United Nations committed to reducing premature mortality from NCDs, including by reducing the burden of healthcare costs. Since 2014, the Prospective Urban and Rural Epidemiology (PURE) Study has been collecting health expenditure data from households with NCDs in 18 countries.

Methods: Using data from the PURE Study, we estimated risk of catastrophic health spending and impoverishment among households with at least one person with NCDs (cardiovascular disease, diabetes, kidney disease, cancer and respiratory diseases; n=17 435), with hypertension only (a leading risk factor for NCDs; n=11 831) or with neither (n=22 654) by country income group: high-income countries (Canada and Sweden), upper middle income countries (UMICs: Brazil, Chile, Malaysia, Poland, South Africa and Turkey), lower middle income countries (LMICs: the Philippines, Colombia, India, Iran and the Occupied Palestinian Territory) and low-income countries (LICs: Bangladesh, Pakistan, Zimbabwe and Tanzania) and China.

Results: The prevalence of catastrophic spending and impoverishment is highest among households with NCDs in LMICs and China. After adjusting for covariates that might drive health expenditure, the absolute risk of catastrophic spending is higher in households with NCDs compared with no NCDs in LMICs (risk difference=1.71%; 95% CI 0.75 to 2.67), UMICs (0.82%; 95% CI 0.37 to 1.27) and China (7.52%; 95% CI 5.88 to 9.16). A similar pattern is observed in UMICs and China for impoverishment. A high proportion of those with NCDs in LICs, especially women (38.7% compared with 12.6% in men), reported not taking medication due to costs.

Conclusions: Our findings show that financial protection from healthcare costs for people with NCDs is inadequate, particularly in LMICs and China. While the burden of NCD care may appear greatest in LMICs and China, the burden in LICs may be masked by care foregone due to costs. The high proportion of women reporting foregone care due to cost may in part explain gender inequality in treatment of NCDs.

Citing Articles

To what extent did households in developing countries forgo needed healthcare during the COVID-19 pandemic? Repeated survey estimates from 25 countries in 2020 and 2021.

Kakietek J, Dayton Eberwein J, Kerr A, Stacey N BMJ Public Health. 2025; 2(2):e001027.

PMID: 40018592 PMC: 11816704. DOI: 10.1136/bmjph-2024-001027.

Cost-of-illness study among patients with diabetes mellitus and coping mechanisms in Northern Ghana.

Ziblim A, Azaare J, Bio R, Inusah A, Issah A, Hushie M BMJ Public Health. 2025; 3(1):e001223.

PMID: 40017986 PMC: 11812882. DOI: 10.1136/bmjph-2024-001223.

Intervention effectiveness in reducing the clustering of non-communicable disease risk factors in the workplace: A quasi-experimental study.

Guesmi N, Ben Fredj S, Zammit N, Ghammam R, Harrabi I, Chouikha F PLoS One. 2025; 20(2):e0317460.

PMID: 39913562 PMC: 11801702. DOI: 10.1371/journal.pone.0317460.

Evaluating catastrophic health expenditures among patients with long bone fractures in Ghana's major teaching hospitals: a hospital-based analysis.

Buunaaim A, Amenah M, Konadu-Yeboah D, Baidoo R, Asare A, Addo W BMC Health Serv Res. 2025; 25(1):82.

PMID: 39815307 PMC: 11734409. DOI: 10.1186/s12913-025-12250-6.

Training of medical coordinators for noncommunicable diseases based on Japanese experience.

Ogawa M, Kobashi Y J Rural Med. 2025; 20(1):46-52.

PMID: 39781299 PMC: 11704599. DOI: 10.2185/jrm.2024-033.

References

Jaspers L, Colpani V, Chaker L, van der Lee S, Muka T, Imo D . The global impact of non-communicable diseases on households and impoverishment: a systematic review. Eur J Epidemiol. 2014; 30(3):163-88. DOI: 10.1007/s10654-014-9983-3. View

Teo K, Chow C, Vaz M, Rangarajan S, Yusuf S . The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009; 158(1):1-7.e1. DOI: 10.1016/j.ahj.2009.04.019. View

Flores G, ODonnell O . Catastrophic medical expenditure risk. J Health Econ. 2016; 46:1-15. DOI: 10.1016/j.jhealeco.2016.01.004. View

Seligman B, Vedanthan R, Fuster V . Acute coronary syndromes in low- and middle-income countries: Moving forward. Int J Cardiol. 2016; 217 Suppl:S10-2. DOI: 10.1016/j.ijcard.2016.06.213. View

Khatib R, Mckee M, Shannon H, Chow C, Rangarajan S, Teo K . Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2015; 387(10013):61-9. DOI: 10.1016/S0140-6736(15)00469-9. View

Beegle K, Frankenberg E, Thomas D . Bargaining power within couples and use of prenatal and delivery care in Indonesia. Stud Fam Plann. 2001; 32(2):130-46. DOI: 10.1111/j.1728-4465.2001.00130.x. View

Murphy A, Jakab M, Mckee M, Richardson E . Persistent low adherence to hypertension treatment in Kyrgyzstan: How can we understand the role of drug affordability?. Health Policy Plan. 2016; 31(10):1384-1390. DOI: 10.1093/heapol/czw080. View

Avezum A, Oliveira G, Lanas F, Lopez-Jaramillo P, Diaz R, Miranda J . Secondary CV Prevention in South America in a Community Setting: The PURE Study. Glob Heart. 2016; 12(4):305-313. DOI: 10.1016/j.gheart.2016.06.001. View

Huffman M, Rao K, Pichon-Riviere A, Zhao D, Harikrishnan S, Ramaiya K . A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One. 2011; 6(6):e20821. PMC: 3114849. DOI: 10.1371/journal.pone.0020821. View

10.

Attaei M, Khatib R, Mckee M, Lear S, Dagenais G, Igumbor E . Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet Public Health. 2017; 2(9):e411-e419. DOI: 10.1016/S2468-2667(17)30141-X. View

11.

Yusuf S, Islam S, Chow C, Rangarajan S, Dagenais G, Diaz R . Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011; 378(9798):1231-43. DOI: 10.1016/S0140-6736(11)61215-4. View

12.

Wang Q, Brenner S, Kalmus O, Banda H, De Allegri M . The economic burden of chronic non-communicable diseases in rural Malawi: an observational study. BMC Health Serv Res. 2016; 16:457. PMC: 5007731. DOI: 10.1186/s12913-016-1716-8. View

13.

Mendis S, Fukino K, Cameron A, Laing R, Filipe Jr A, Khatib O . The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007; 85(4):279-88. PMC: 2636320. DOI: 10.2471/blt.06.033647. View

14.

Lund C, Docrat S, Abdulmalik J, Alem A, Fekadu A, Gureje O . Household economic costs associated with mental, neurological and substance use disorders: a cross-sectional survey in six low- and middle-income countries. BJPsych Open. 2019; 5(3):e34. PMC: 6469228. DOI: 10.1192/bjo.2019.20. View

15.

Wagstaff A, Flores G, Hsu J, Smitz M, Chepynoga K, Buisman L . Progress on catastrophic health spending in 133 countries: a retrospective observational study. Lancet Glob Health. 2017; 6(2):e169-e179. DOI: 10.1016/S2214-109X(17)30429-1. View

16.

Corsi D, Subramanian S . Socioeconomic Gradients and Distribution of Diabetes, Hypertension, and Obesity in India. JAMA Netw Open. 2019; 2(4):e190411. PMC: 6450330. DOI: 10.1001/jamanetworkopen.2019.0411. View

17.

Murphy A, Mahal A, Richardson E, Moran A . The economic burden of chronic disease care faced by households in Ukraine: a cross-sectional matching study of angina patients. Int J Equity Health. 2013; 12:38. PMC: 3691525. DOI: 10.1186/1475-9276-12-38. View

18.

Kruk M, Goldmann E, Galea S . Borrowing and selling to pay for health care in low- and middle-income countries. Health Aff (Millwood). 2009; 28(4):1056-66. DOI: 10.1377/hlthaff.28.4.1056. View

19.

DAYTON J, Demery L, Mehra K . Public spending on health care in Africa: do the poor benefit?. Bull World Health Organ. 2000; 78(1):66-74. PMC: 2560601. View

20.

Murphy A, Palafox B, ODonnell O, Stuckler D, Perel P, Alhabib K . Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. Lancet Glob Health. 2018; 6(3):e292-e301. PMC: 5905400. DOI: 10.1016/S2214-109X(18)30031-7. View